This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up
by Zacks Equity Research
A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results
Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat
by Zacks Equity Research
Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.
McKesson (MCK) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.
Avanos (AVNS) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Avanos (AVNS) Q1 results benefit from higher revenues, strong segmental performance and expansion in margins.
Allscripts (MDRX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Allscripts (MDRX) Q1 results gain from growth in bookings and solid show by client services segment. Contraction in margins remains a woe.
Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Genomic Health (GHDX) registers strong year-over-year growth in revenues on solid domestic and overseas performances.
Inogen (INGN) Earnings Miss Estimates in Q1, View Lowered
by Zacks Equity Research
Inogen (INGN) slashes revenue and net income guidance for 2019.
DaVita (DVA) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
DaVita (DVA) gains from international revenues in Q1.
Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up
by Zacks Equity Research
Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.
Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates
by Urmimala Biswas
Henry Schein's (HSIC) strong share gains in the North American market raise optimism.
Intersect (XENT) Q1 Loss Wider Than Estimates, Revenues Top
by Zacks Equity Research
Intersect (XENT) records revenue growth on increased adoption of the PROPEL family of products and SINUVA Sinus Implant.
QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.
Masimo (MASI) Q1 Earnings and Revenues Beat, Guidance Solid
by Zacks Equity Research
Solid non-invasive revenues boost Masimo's (MASI) Q1; guidance raised.
Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall
by Zacks Equity Research
Pacific Biosciences' (PACB) segments see softness in Q1; merger with Illumina on track.
Luminex (LMNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Luminex (LMNX) Q1 results gain from higher revenues from System sales, Royalty as well as Service segments. However, contraction in gross margin remains a woe.
Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical (FMS) gains from solid international revenues in Q1.
HMS Holdings' (HMSY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Top-line growth, higher commercial and state government revenues and expansion in margins aid HMS Holdings (HMSY) in Q1 earnings. However, increase in cost of services remains a woe.
Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Top-line growth and better performance at Medical and Non-Medical segments benefit Integer Holdings' (ITGR) Q1 results. However, contraction in gross margin remains a dampener.
AMN Healthcare (AMN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Higher revenues and expansion in gross margin find reflection in AMN Healthcare's (AMN) Q1 results. However, weak performance at Nurse and Allied and Locum Tenens segments remain woes.
Globus Medical (GMED) Q1 Earnings Miss, Revenues Grow Y/Y (Revised)
by Zacks Equity Research
Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) Q1 earnings gain from Technology & Equipment unit despite international revenues being down.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Insulet (PODD) registers year-over-year improvement in revenues on solid uptake of Omnipod system both in the United States and international markets.
Medidata (MDSO) Q1 Earnings Beat Estimates, Margins fall
by Zacks Equity Research
Medidata (MDSO) witnesses year-over-year revenue growth in double-digits across both operating segments in first-quarter 2019.
PRA Health (PRAH) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
PRA Health's (PRAH) Q1 earnings reflect top-line growth, favorable segmental performance and margin expansion.